

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (withdrawn)
Claims 12-14 (canceled)
Claim 15 (withdrawn)
Claims 16-17 (canceled)
Claims 18-23 (withdrawn)
Claims 24-25 (canceled)
Claims 26-31 (withdrawn)
Claims 32-34 (canceled)
Claims 35-36 (withdrawn)
Claim 37 (canceled)
Claims 38-46 (withdrawn)

Claim 47 (previously presented): A membrane preparation comprising the human KDR protein which consists of the amino acid sequence as set forth in SEQ ID NO: 2, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the human KDR protein.

Claim 48 (currently amended): A membrane preparation comprising a protein fragment which is an intracellular portion of a human KDR protein, comprising from about amino acid ~~772~~ 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the human KDR protein fragment.

Claim 49 (currently amended): A membrane preparation ~~comprising a protein fragment which is an intracellular portion of a human KDR protein of claim 48, comprising from about amino acid 772 to about amino acid 1356 as set forth in SEQ ID NO: 2,~~ wherein position 772 is an alanine residue, position 787 is an arginine residue, position 835 is a lysine residue, position 848 is a valine residue and position 1347 is a serine residue, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the human KDR protein fragment.

Claim 50 (currently amended): A membrane preparation comprising a KDR fusion protein comprising a KDR protein and a heterologous protein, wherein the KDR protein is characterized by an intracellular portion of a human KDR protein, comprising from about amino acid ~~772~~ 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the human KDR fusion protein.

Claim 51 (currently amended): A membrane preparation ~~comprising a KDR fusion protein comprising a KDR protein and a heterologous protein, wherein the KDR protein is characterized by an intracellular portion of a human KDR protein of claim 50, comprising from about amino acid 772 to about amino acid 1356 as set forth in SEQ ID NO: 2,~~ wherein position 772 is an alanine residue, position 787 is an arginine residue, position 835 is a lysine residue, position 848 is a valine residue and position 1347 is a serine residue, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the human KDR fusion protein.

Claim 52 (previously presented): A membrane preparation according to claim 51 wherein the heterologous protein is GST.

Claim 53 (new): A method of selecting a compound which antagonizes human KDR, the method comprising combining

a test compound

a membrane preparation comprising a protein comprising from about amino acid 790 to about amino acid 1356 as set forth in SEQ ID NO: 2, wherein position 848 is a valine residue, wherein said membrane preparation is obtained from a recombinant host cell transformed or transfected with a DNA molecule encoding the protein, and

a substrate that is involved in a measurable interaction at a domain of interest within wild-type KDR such that a compound antagonist interacts with said KDR, resulting in a measurable decrease in KDR:substrate activity.

Claim 54 (new): A method of claim 41 wherein said protein is GST/KDR-1.

Claim 55 (new): A method of claim 42 wherein said substrate is pEY.